Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline extends price freeze commitment for Gavi-eligible countries

GlaxoSmithKline extends price freeze commitment for Gavi-eligible countries

2nd February 2015

GlaxoSmithKline has announced that it will be extending its price freeze commitment for countries that receive aid to improve vaccination access from the Gavi Alliance.

Under the new deal, developing countries that graduate from Gavi support due to increased economic wealth will be able to continue to purchase vaccines against pneumonia, diarrhoea and cervical cancer at significantly discounted prices for up to ten years after graduation.

From 2016, 22 countries with growing economies will begin to graduate from Gavi support, so this new arrangement will make it easier for these nations to develop their own independence, while helping Gavi to focus its resources on the poorest nations.

The Gavi Alliance is a private-public partnership which aims to increase access to vaccination in 73 of the world's poorest countries. GlaxoSmithKline is one of its longest-serving partners.

Sir Andrew Witty, chief executive officer of GlaxoSmithKline, said: "Our extended price freeze is designed to bring vaccine price stability for graduating countries, ensuring sustainability of the Gavi model and helping more children benefit from national immunisation programmes."

Last month, the firm achieved a milestone in the development of its new Ebola vaccine, shipping the first batch of the product to help fight the deadly disease in Liberia.ADNFCR-8000103-ID-801773309-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.